| EU Biotech Development Limited |
| Registered number: |
SC199767 |
| Balance Sheet |
| as at 28 February 2026 |
|
| Notes |
|
|
2026 |
|
|
2025 |
| £ |
£ |
| Fixed assets |
| Tangible assets |
3 |
|
|
27,835 |
|
|
37,113 |
|
| Current assets |
| Cash at bank |
|
|
220,812 |
|
|
272,687 |
|
| Creditors: amounts falling due within one year |
4 |
|
(307,162) |
|
|
(332,415) |
|
| Net current liabilities |
|
|
|
(86,350) |
|
|
(59,728) |
|
| Net liabilities |
|
|
|
(58,515) |
|
|
(22,615) |
|
|
|
|
|
|
|
|
| Capital and reserves |
| Called up share capital |
|
|
|
10,000 |
|
|
10,000 |
| Profit and loss account |
|
|
|
(68,515) |
|
|
(32,615) |
|
| Shareholders' funds |
|
|
|
(58,515) |
|
|
(22,615) |
|
|
|
|
|
|
|
|
| The director is satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006. |
| The members have not required the company to obtain an audit in accordance with section 476 of the Act. |
| The director acknowledges her responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. |
| The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies. |
|
|
|
|
| M S Choung |
| Director |
| Approved by the board on 8 September 2026 |
|
| EU Biotech Development Limited |
| Notes to the Accounts |
| for the year ended 28 February 2026 |
|
|
| 1 |
Accounting policies |
|
|
Basis of preparation |
|
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard). |
|
|
Tangible fixed assets |
|
Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows: |
|
|
Plant and machinery |
25% reducing balance |
|
|
Creditors |
|
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method. |
|
|
| 2 |
Employees |
2026 |
|
2025 |
| Number |
Number |
|
|
Average number of persons employed by the company |
2 |
|
2 |
|
|
|
|
|
|
|
|
|
|
| 3 |
Tangible fixed assets |
|
|
|
|
|
|
|
|
Plant and machinery etc |
| £ |
|
Cost |
|
At 1 March 2025 |
156,393 |
|
At 28 February 2026 |
156,393 |
|
|
|
|
|
|
|
|
|
|
Depreciation |
|
At 1 March 2025 |
119,280 |
|
Charge for the year |
9,278 |
|
At 28 February 2026 |
128,558 |
|
|
|
|
|
|
|
|
|
|
Net book value |
|
At 28 February 2026 |
27,835 |
|
At 28 February 2025 |
37,113 |
|
|
| 4 |
Creditors: amounts falling due within one year |
2026 |
|
2025 |
| £ |
£ |
|
|
Trade creditors |
266,119 |
|
266,119 |
|
Other creditors |
41,043 |
|
66,296 |
|
|
|
|
|
|
307,162 |
|
332,415 |
|
|
|
|
|
|
|
|
|
|
| 5 |
Other information |
|
|
EU Biotech Development Limited is a private company limited by shares and incorporated in Scotland. Its registered office is: |
|
1 George Square |
|
Glasgow |
|
G2 1AL |